Is DYSPNOEA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DYSPNOEA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 131 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DYSPNOEA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DYSPNOEA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DYSPNOEA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DYSPNOEA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DYSPNOEA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DYSPNOEA: 131
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DYSPNOEA is a reported side effect: 3.9351%

FDA reports of any drug causing DYSPNOEA : 150474
Average percentage for all medicated patients where DYSPNOEA is reported as a complication: 0.9431%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DYSPNOEA:

ASPIRIN (13522 patients)
VIOXX (9534 patients)
SPIRIVA (7822 patients)
HEPARIN SODIUM INJECTION (6835 patients)
LASIX (6748 patients)
ALBUTEROL (6247 patients)
REMICADE (5956 patients)
PREDNISONE (5829 patients)
ADVAIR DISKUS 100/50 (5715 patients)
LISINOPRIL (5617 patients)
LIPITOR (5569 patients)
FOSAMAX (5093 patients)
NEXIUM (5083 patients)
FUROSEMIDE (5042 patients)
COUMADIN (5026 patients)
HUMIRA (4639 patients)
SYNTHROID (4630 patients)
ZOMETA (4327 patients)
OMEPRAZOLE (4321 patients)
DIGOXIN (4107 patients)
PLAVIX (4086 patients)
SIMVASTATIN (4063 patients)
SYMBICORT (3999 patients)
FOLIC ACID (3657 patients)
XANAX (3589 patients)
ATENOLOL (3545 patients)
METHOTREXATE (3501 patients)
SEROQUEL (3396 patients)
FORTEO (3349 patients)
HYDROCHLOROTHIAZIDE (3317 patients)
PRILOSEC (3203 patients)
SINGULAIR (3159 patients)
LYRICA (3134 patients)
POTASSIUM CHLORIDE (3130 patients)
NORVASC (3117 patients)
ACETAMINOPHEN (3076 patients)
PROTONIX (3067 patients)
TOPROL-XL (3039 patients)
ZOCOR (2995 patients)
NEURONTIN (2993 patients)
LEVOTHYROXINE SODIUM (2973 patients)
AMBIEN (2968 patients)
CELEBREX (2921 patients)
YAZ (2867 patients)
DEXAMETHASONE (2686 patients)
ZOLOFT (2684 patients)
TRACLEER (2684 patients)
ENBREL (2671 patients)
IBUPROFEN (2661 patients)
YASMIN (2632 patients)
METFORMIN HCL (2597 patients)
AVANDIA (2596 patients)
ALLOPURINOL (2581 patients)
WARFARIN SODIUM (2567 patients)
PREDNISONE TAB (2506 patients)
DIOVAN (2485 patients)
CHANTIX (2474 patients)
OXYCONTIN (2467 patients)
METOPROLOL TARTRATE (2389 patients)
VITAMIN D (2373 patients)
VICODIN (2364 patients)
XOLAIR (2336 patients)
PREDNISOLONE (2285 patients)
PREVACID (2285 patients)
LORAZEPAM (2268 patients)
AREDIA (2257 patients)
ATIVAN (2247 patients)
COREG (2214 patients)
CRESTOR (2189 patients)
LEVAQUIN (2165 patients)
LEXAPRO (2115 patients)
CYMBALTA (2107 patients)
PAXIL (2089 patients)
LANTUS (2073 patients)
BENADRYL (2051 patients)
COMBIVENT (2044 patients)
AVONEX (2025 patients)
ZOFRAN (2001 patients)
AMLODIPINE (1997 patients)
PERCOCET (1993 patients)
NITROGLYCERIN (1956 patients)
LETAIRIS (1916 patients)
GABAPENTIN (1914 patients)
CARBOPLATIN (1884 patients)
SANDOSTATIN LAR (1872 patients)
SPIRONOLACTONE (1846 patients)
CALCIUM (1844 patients)
AVELOX (1810 patients)
INSULIN (1765 patients)
MORPHINE (1750 patients)
VENTOLIN (1730 patients)
OXYGEN (1708 patients)
DECADRON (1690 patients)
TYSABRI (1675 patients)
ALPRAZOLAM (1651 patients)
DURAGESIC-100 (1646 patients)
REVLIMID (1639 patients)
OXYCODONE HCL (1635 patients)
PREMARIN (1628 patients)
MULTI-VITAMIN (1574 patients)
ZANTAC (1570 patients)
CLONAZEPAM (1562 patients)
PROZAC (1551 patients)
LORTAB (1545 patients)
METOPROLOL (1538 patients)
ZYRTEC (1538 patients)
EFFEXOR (1527 patients)
MULTI-VITAMINS (1512 patients)
ALLEGRA (1504 patients)
RIBAVIRIN (1502 patients)
AMOXICILLIN (1487 patients)
TAXOTERE (1474 patients)
CYCLOPHOSPHAMIDE (1444 patients)
TRAMADOL HCL (1421 patients)
GLEEVEC (1413 patients)
GLUCOPHAGE (1413 patients)
COZAAR (1404 patients)
RANITIDINE (1401 patients)
RAMIPRIL (1400 patients)
DIANEAL (1396 patients)
FLOVENT (1375 patients)
HEPARIN SODIUM (1361 patients)
PEGASYS (1354 patients)
CARVEDILOL (1329 patients)
ACTOS (1319 patients)
LOVENOX (1318 patients)
VITAMIN B-12 (1317 patients)
TYLENOL (CAPLET) (1313 patients)
DIAZEPAM (1292 patients)
WELLBUTRIN (1278 patients)
ENALAPRIL MALEATE (1276 patients)
FLONASE (1261 patients)
ALDACTONE (1240 patients)
PACLITAXEL (1239 patients)
KLONOPIN (1239 patients)
TYLENOL (1235 patients)
FLEXERIL (1204 patients)
ALTACE (1202 patients)
LOPRESSOR (1201 patients)
BYETTA (1197 patients)
CELEXA (1193 patients)
FISH OIL (1189 patients)
LANSOPRAZOLE (1182 patients)
FLUOROURACIL (1174 patients)
FENTANYL (1173 patients)
NAPROXEN (1172 patients)
ASCORBIC ACID (1169 patients)
REGLAN (1169 patients)
ATROVENT (1167 patients)
COMPAZINE (1162 patients)
COLACE (1160 patients)
VALIUM (1158 patients)
ZITHROMAX (1153 patients)
GLIPIZIDE (1145 patients)
CLONIDINE (1140 patients)
CISPLATIN (1139 patients)
VELCADE (1120 patients)
MORPHINE SULFATE (1116 patients)
METFORMIN (1112 patients)
ZETIA (1108 patients)
TAXOL (1106 patients)
TRAZODONE HCL (1105 patients)
REVATIO (1102 patients)
ARANESP (1102 patients)
FLOMAX (1095 patients)
PANTOPRAZOLE (1089 patients)
VERAPAMIL (1079 patients)
MAGNEVIST (1061 patients)
ZYPREXA (1055 patients)
GLYBURIDE (1054 patients)
POTASSIUM (1048 patients)
CALCIUM CARBONATE (1039 patients)
METOPROLOL SUCCINATE (1020 patients)
FERROUS SULFATE TAB (1019 patients)
DILAUDID (1018 patients)
CLARITIN (1011 patients)
HEPARIN (1002 patients)
CARDIZEM (995 patients)
HUMALOG (993 patients)
AMITRIPTYLINE HCL (990 patients)
CIPROFLOXACIN (977 patients)
PEPCID (973 patients)
CLOZARIL (964 patients)
AMIODARONE HCL (963 patients)
IRON (946 patients)
TEMAZEPAM (944 patients)
VITAMIN E (938 patients)
FLUCONAZOLE (937 patients)
EXJADE (936 patients)
TOPAMAX (934 patients)
METOCLOPRAMIDE (926 patients)
NIASPAN (924 patients)
SOLU-MEDROL (921 patients)
NEXAVAR (918 patients)
PRAVASTATIN (914 patients)
XOPENEX (913 patients)
XELODA (906 patients)
DOCETAXEL (904 patients)
SEREVENT (900 patients)
MOTRIN (899 patients)
ACYCLOVIR (890 patients)
PRADAXA (890 patients)
SOLIRIS (885 patients)
HYDROCODONE (883 patients)
KLOR-CON (881 patients)
AZITHROMYCIN (879 patients)
AFINITOR (878 patients)
REBIF (877 patients)
BACTRIM (869 patients)
ADVAIR HFA (867 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DYSPNOEA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.